Loading clinical trials...
Loading clinical trials...
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease, an In Situ Small Bowel T Cell Lymphoma
Protocol CELIM-RCD-002 is designed to evaluate the efficacy and safety of AMG 714 for the treatment of adult patients with type II refractory celiac disease (RCD-II), an in-situ small bowel T-cell lymphoma.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Clinical Site
San Diego, California, United States
Clinical Site
New York, New York, United States
Clinical Site
Tampere, Finland
Clinical Site
Paris, France
Clinical Site
Amsterdam, Netherlands
Clinical Site
Madrid, Spain
Start Date
April 13, 2016
Primary Completion Date
April 11, 2017
Completion Date
May 2, 2017
Last Updated
December 27, 2019
28
ACTUAL participants
AMG 714
BIOLOGICAL
Placebo
BIOLOGICAL
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions